Document is current
Any future updates will be listed below
-
Authors
Foilb, Allison R. http://orcid.org/0000-0003-0049-1930
Taylor-Yeremeeva, Elisa M.
Schmidt, Brett D.
Ressler, Kerry J. http://orcid.org/0000-0002-5158-1103
Carlezon, William A. Jr. http://orcid.org/0000-0002-4162-3947
-
Funding
Funding for this research was provided by:
Rappaport Mental Health Research Scholar Award from the Phyllis & Jerome Lyle Rappaport Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (P50MH115874, P50MH115874, R01MH063266)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 30 May 2024
Revised: 8 August 2024
Accepted: 21 August 2024
First Online: 28 August 2024
Competing interests
: WAC and KJR are members of the NPP editorial board. WAC is a consultant for Psy Therapeutics and has sponsored research agreements with Cerevel Therapeutics and Delix Therapeutics. KJR has performed scientific consultation for Bioxcel, Bionomics, Acer, Takeda, and Jazz Pharma; serves on Scientific Advisory Boards for Sage and the Brain Research Foundation, and he has received sponsored research support from Takeda, Brainsway, and Alto Neuroscience. ARF, EMTY, and BDS report no competing interests.
